CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: A case report and literature review

Keyphrases

• Acute Abdominal Pain 33%
• African American Men 33%
• Aggressive Phenotype 33%
• Alemtuzumab 100%
• Celiac Disease 66%
• Clinical Response 33%
• Cyclophosphamide 33%
• Diagnostic Challenge 33%
• Doxorubicin 33%
• Enteropathy-associated T-cell Lymphoma 100%
• Fatal Outcome 33%
• Fluorodeoxyglucose 33%
• Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) 100%
• Gastrointestinal Tolerance 33%
• Long-term Benefit 100%
• Lymphoma Diagnosis 33%
• Malignancy 33%
• Metabolic Response 100%
• Non-Hodgkin Lymphoma 33%
• Older African Americans 33%
• Poor Outcome 33%
• Positron Emission Tomography 33%
• Prednisone 33%
• Radiological Response 33%
• Rare Subtype 33%
• Subacute Course 33%
• Therapeutic Challenges 33%
• Treatment Monitoring 33%
• Uncommon Diseases 33%
• Weight Loss 33%

Medicine and Dentistry

• Acute Abdomen 33%
• Alemtuzumab 100%
• Cancer 33%
• CHOP 100%
• Coeliac Disease 66%
• Cyclophosphamide 33%
• Deoxyglucose 33%
• Diagnosis 33%
• Diseases 66%
• Doxorubicin 33%
• Enteropathy-Associated T-Cell Lymphoma 100%
• Fatality 33%
• Metabolism 100%
• Non-Hodgkin Lymphoma 33%
• Polyethylene Terephthalate 100%
• Positron Emission Tomography 33%
• Prednisone 33%
• Treatment Response 33%
• Vincristine 33%